Chinese officials are expected to be in Washington this week to hold consultations with the U.S. ahead of high-level trade talks in October.World Economyread more
The ballot comes at a precarious time for the country's longest serving prime minister, with the right-wing incumbent facing formidable challenges.World Politicsread more
Saudi Arabia's defense spending is the world's third-largest — behind the U.S. and China, says Gary Grappo, former U.S. ambassador to Oman.Energyread more
President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
British biotech GW Pharmaceuticals took one step closer to having its key childhood epilepsy drug Epidiolex approved on Monday, when it announced promising phase 3 clinical trial results. Shares of the stock soared more than 17 percent in response.
In an interview with Jim Cramer on Monday, GW Pharma CEO Justin Gover said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite the medication, they still had three seizures a day, approximately 90 a month.
"The impact that we have had that we have shown today is a hugely important potential breakthrough in the treatment of the condition called Lennox-Gastaut syndrome," Gover told the host of CNBC's "Mad Money."
Epidiolex is an orphan drug that is pharmaceutical cannabidiol, not medical marijuana. The drug helps treat various types of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. GW Pharma's study revealed that patients taking 20 mg of Epidiolex had a medium reduction in monthly seizures of 42 percent versus a 17 percent reduction for those on placebo.
"The good news is this is actually the third positive trial within the field of treatment resistant childhood onset epilepsy that we have reported results for in the last six months," Gover said.
The company said it expects to file a new drug application with the FDA in the first half of 2017. GW Pharma is a U.K. based biotech that grows its own cannabis plants — the scientific name for marijuana — to study the ingredients, and then synthesizes it into medicine.
The company already has one product on the market called Sativex, which is a mouth spray to treat spasms for multiple sclerosis.
There are currently no FDA-approved treatments for Dravet syndrome. Patients often experience prolonged and severe seizures early in life, along with developmental delays.
"Of course, we still have yet to apply to the FDA and to have approval. But this is a huge step on that journey," Gover said.